Global Overt Hepatic Encephalopathy Treatment Market - 2023-2030

Global Overt Hepatic Encephalopathy Treatment Market - 2023-2030

Global overt hepatic encephalopathy treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.

The global overt hepatic encephalopathy treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The symptomatic impairment of normal brain function brought on by hepatic failure and/or portosystemic shunting is known as overt hepatic encephalopathy. About 40% of cirrhotic patients experience it during their therapeutic treatment. In 40% of individuals, a first incidence of overt encephalopathy signals recurrence.

Government investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like laxatives or antibiotics and boost the global overt hepatic encephalopathy treatment market. The respective innovative treatment are being developed by several researchers and currently are under trials.

Market Dynamics: Drivers & Restraints

Growing funding and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for overt hepatic encephalopathy treatment owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On March 28, 2023, the company's medication development initiatives are moving forward thanks to fresh finance of SEK 31,6 million obtained by Umecrine Cognition. To treat cognitive disorders, Umecrine Cognition is creating a new class of medicines. Currently being developed for the treatment of individuals with hepatic encephalopathy (HE; liver coma) and primary biliary cholangitis (PBC), golexanolone is the company's most advanced medication candidate.

Due to the severe diseases' impact on brain function, symptoms such intense weariness, trouble concentrating, and poor motor coordination develop. Previous clinical or pre-clinical study findings overwhelmingly support the idea that golexanolone can compensate for such impaired brain function.

Furthermore, the rising utilization of novel technology with high level of research for the several development purposes. Rising overt hepatic encephalopathy cases and increasing research for innovative treatment development will be a major factor driving the growth of the overt hepatic encephalopathy treatment market.

Side effects associated with the overt hepatic encephalopathy medications

Because rifaximin is not absorbed systemically, it is well tolerated. The dropout rates for adverse events in controlled trials were 0.4% for both rifaximin and the placebo. Anorexia, diarrhea, taste loss, and nasal passage discomfort are rare side effects. Rifaximin patients may experience negative medication effects such as nausea, stomach upset, weariness, dizziness, peripheral edema, and muscular spasms.

Long-term use has also been linked to bacterial or fungal super-infections. Despite its extensive usage, there is minimal proof that rifaximin increases serum enzyme levels or causes clinically obvious liver damage.

Segment Analysis

The global overt hepatic encephalopathy treatment market is segmented based on medications, route of administration, distribution channel and region.

Antibiotics segment accounted for approximately 39% of market share

A non-absorbable oral antibiotic is rifaximin. In addition to treating travelers' diarrhea brought on by noninvasive Escherichia coli strains, rifaximin is also used to treat overt hepatic encephalopathy in adults and manage irritable bowel syndrome associated diarrhea. Rifaximin is active against a wide range of anaerobic and aerobic gram-positive and gram-negative bacteria.

Due to its non-absorbable nature, this antibiotic is mostly used to treat infections that affect the gastrointestinal tract. Rifaximin is non-absorbable, which enables it to accumulate to high concentrations in the gastrointestinal lumen where it can treat a variety of gastrointestinal illnesses without causing systemic side effects. Bacterial transformation or drug resistance to rifaximin are extremely rare in extra-intestinal microorganisms.

On June 22, 2023, an application for a partial change to the production and distribution authorization for RIFXIMA TABLETS (rifaximin) has been submitted by ASKA Pharmaceutical Co., Ltd., a wholly owned subsidiary of ASKA Pharmaceutical Holdings Co., Ltd., for an increase in dosage and administration to pediatric patients for the treatment of hyperammonemia in hepatic encephalopathy.

Geographical Penetration

North America accounted for around 35% of market share in 2022

Due to the rising need for overt hepatic encephalopathy treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for overt hepatic encephalopathy treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of medicines, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of overt hepatic encephalopathy treatment market share of this region. The market in this area is growing as people become more aware of various novel approved medicines. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global overt hepatic encephalopathy treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for overt hepatic encephalopathy treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating overt hepatic encephalopathy treatment demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global overt hepatic encephalopathy treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various medicines, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for overt hepatic encephalopathy treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global overt hepatic encephalopathy treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative treatment.

Key Developments
• On June 19, 2023, the XIFAXAN (rifaximin) data was provided by Bausch Health Companies Inc. and Salix Pharmaceuticals, its gastrointestinal division, and was chosen for inclusion in the Cirrhosis and its consequences session at the 2023 European Association for the Study of the Liver (EASL) Congress.
• On June 30, 2021, AXA1665, the Axcella's multi-targeted oral item candidate for lowering risk of persistent overt hepatic encephalopathy (OHE), has entered its initial clinical sites and screened patients for its worldwide Phase 2 clinical trial. Axcella is a biotechnology clinical-stage company that has invented a new approach for treating complex diseases and enhance health utilizing endogenous metabolic modulator (EMM) compositions.

Competitive Landscape

The major global players in the market include Axcella Therapeutics, COSMO PHARMACEUTICALS, Umecrine Cognition AB, Salix Pharmaceuticals (Bausch Health Companies Inc.), ASKA Pharmaceutical Holdings Co., Ltd., Lupin, Norgine, Teva Pharmaceutical Industries Ltd., Fresenius Kabi Austria GmbH and Fengchen Group Co.,Ltd.

Why Purchase the Report?
• To visualize the global overt hepatic encephalopathy treatment market segmentation based on medications, route of administration, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of overt hepatic encephalopathy treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global overt hepatic encephalopathy treatment market report would provide approximately 61 tables, 59 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies